|Bid||1.4600 x 900|
|Ask||1.4900 x 1800|
|Day's Range||1.4500 - 1.4900|
|52 Week Range||1.0200 - 4.5000|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||0.87|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.85|
Ophthotech Corporation (OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell and Gene Therapy Investor Day in New York, NY, on Thursday, March 21, 2019 at 2:15 p.m. Eastern Time. A live video webcast of Dr. Rezaei’s presentation will be available at: http://www.arminvestorday.com/webcast. An archived replay of the webcast will be available on the Company’s website at www.ophthotech.com for 14 days after the conference.
Ophthotech Corporation (NASDAQ:OPHT) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking declineRead More...
Ophthotech Corporation (OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer of Ophthotech, will present an overview of the Company at the Cowen and Company 39th Annual Health Care Conference in Boston, MA, on Wednesday, March 13, 2019 at 9:20 a.m. Eastern Time. Any forward-looking statements represent Ophthotech's views only as of the date of this press release.
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Ophthotech Corporation today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Ophthotech Corporation (OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Dr. Roberts is Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell Univ
Dr. Graves is well-known in the ophthalmology community and for her successful track record in building organizations and overseeing innovative ophthalmic products through the development, regulatory and commercialization process in the U.S. and globally. “We are excited to welcome Dr. Graves, a highly-respected executive in our industry, to our Board of Directors,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech and David R. Guyer, M.D., Executive Chairman of Ophthotech.
Every investor in Ophthotech Corporation (NASDAQ:OPHT) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ophthotech Corporation (OPHT) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD and was the first in human trial assessing the safety of Zimura 4mg dose in combination with Lucentis® (ranibizumab) 0.5mg, an anti-vascular endothelial growth factor (anti-VEGF). Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with anti-VEGF drugs.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.
The New York-based company said it had a loss of 41 cents per share. The company's shares closed at $2.26. A year ago, they were trading at $2.31. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive option agreement with the University of Pennsylvania (Penn) and the University of Florida Research Foundation (UFRF) for rights to negotiate to acquire an exclusive global license to develop and commercialize novel adeno-associated virus (AAV) gene therapy product candidates for the treatment of Best vitelliform macular dystrophy, also known as Best disease. Best disease, which generally affects individuals in both eyes, is an orphan inherited degenerative retinal disease caused by mutations in the BEST1 gene.
Ophthotech Corporation (OPHT) announced today that it has acquired Inception 4, Inc., a privately held company backed by Versant Ventures, expanding Ophthotech’s therapeutic pipeline in age-related retinal indications. HtrA1 is potentially implicated in a range of retinal diseases including geographic atrophy, an advanced form of dry age-related macular degeneration (AMD).
Ophthotech Corporation today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
Ophthotech Corporation (OPHT) announced completion of patient recruitment for its Phase 2b clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). A total of 286 patients have been enrolled into this randomized, double-masked, sham controlled multi-center clinical trial. This clinical trial is designed to assess the safety and efficacy of various Zimura dosing regimens over 12 months.